Method and kit for following neurodegenerative diseases
AssigneeGemac
InventorMichel Geffard
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for detecting and supervising neurodegenerative diseases, which consists in detecting the presence of antibodies of the A-isotype and/or M-isotype which are directed against the antigens which are associated with these diseases. The invention also relates to a kit for the implementation of this method.
Claims27
A method of detecting antibodies which are associated with the occurrence or the progression of Multiple Sclerosis in a biological fluid, which comprises the following steps:
- placing said fluid in contact with each one of the following antigens:
- Pl, Ach, Aze, NO-Cys, NO-Tyr, NO-Trp, NO2-Tyr, NO-Asn, NO-Met, Ig5, Ig12, Ig13, Ig16, Ig17 and Ig19,
- wherein Pl, Ach, Aze, NO-Cys, NO-Tyr, NO-Trp, NO2-Tyr, NO-Asn, NO-Met are non-bacterial antigens and wherein Ig5, Ig12, Ig13, Ig16, Ig17 and Ig19 are bacterial antigens, and
- revealing the complexes which are formed between said antigens and the corresponding antibodies,
- wherein said antibodies are of the A-isotype for bacterial antigens Ig5, Ig12, Ig13, Ig16 and Ig19, and of the M-isotype for bacterial antigens Ig12 and Ig17.
A method of detecting antibodies which are associated with the occurrence or the progression of Amyotrophical Lateral Sclerosis in a biological fluid, which comprises the following steps:
- placing said fluid in contact with each one of the following antigens:
- Ole, Pl, MDA, Aze, NO-Cys, FarCys, Ig3, Ig5, Ig12, Ig13, Ig16 and Ig17,
- wherein Ole, Pl, MDA, Aze, NO-Cys, FarCys are non-bacterial antigens and wherein Ig3, Ig5, Ig12, Ig13, Ig16 and Ig17 are bacterial antigens, and
- revealing the complexes which are formed between said antigens and the corresponding antibodies,
- wherein said antibodies are of the A-isotype for bacterial antigens Ig3, Ig5, Ig12, Ig13, Ig16 and Ig17, and of the M-isotype for bacterial antigens Ig3, Ig12, Ig13, Ig16 and Ig17.
A method of detecting antibodies which are associated with the occurrence or the progression of Rheumatoid Arthritis in a biological fluid, which comprises the following steps:
- placing said fluid in contact with each one of the following antigens:
- Pal, Ole, Myr, Pl, MDA, FarCys, Aze, NO-Cys, NO-Phe, Ig3, Ig5, Ig12, Ig13, Ig17 and Ig19,
- wherein Pal, Ole, Myr. Pl, MDA, FarCys, Aze, NO-Cys, NO-Phe are non-bacterial antigens and wherein Ig3, Ig5, Ig12, Ig13, Ig17 and Ig19 are bacterial antigens, and
- revealing the complexes which are formed between said antigens and the corresponding antibodies,
- wherein said antibodies are of the A-isotype for bacterial antigens Ig3, Ig5, Ig12 and Ig19, and of the M-isotype for bacterial antigens Ig3, Ig5, Ig12, Ig13 and Ig17.
Dependencies are inferred from the claim text.